

Compendium of Organisational Outputs (Immunocompromised Individuals and specific disease)

About the compendium

This compendium contains a list of organisational outputs in relation to Vaccination of Immunocompromised Individuals and specific diseases including, guidance, tools, education resources, literature reviews and research by specialist organisations and any additional documents that are applicable for use in NHSScotland for example, Department of Health and specialist advisory bodies.

This compendium aims to provide NHSScotland staff with an overview of all materials available relating to immunisation of persons with underlying medical conditions and specific diseases.

The compendium is indexed by document type and organisation setting.

The compendium will be updated when new materials are available.

No responsibility will be taken for any omissions to or the content of the compendium. Any questions regarding any of the guidance documents should be directed to the appropriate organisation.

If you are aware of any additional materials for inclusion in the compendium please notify the Scottish Immunisation Programme via NSS.HPSimmunisation@nhs.net

New documents added to the compendium as at October 2016

Document Title	Issuing body
Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).	CDC
Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).	CDC
British HIV Association guidelines for immunization of HIV infected adults 2008	BIVA
Immunisation of the Immunocompromised Child. Best Practice Statement	RCPCH
de la Fuente Garcia, Isabel, et al. "Protection against vaccine preventable diseases in children treated for acute lymphoblastic leukemia." <i>Pediatric Blood & Cancer</i> (2016).	PBC

Index by Document Type

Guidance
Surveillance
Tools / Implementation
Education Resources
Literature Reviews
Research

Index by Document relevance to Care Setting

Acute
Community

Index by Author

Advisory Committee for Immunization Practices
British Committee for Standards in Haematology
British Geriatrics Society
British HIV Association
British Society for Rheumatology
British Transplantation Society
Children's Cancer and Leukaemia Group
Department of Health – The Green Book
European Bone Marrow Transplant
Health Improvement Scotland
Health Protection Scotland

Lymphoma Association
Immunisation Scotland
Infectious Diseases Society of America
International Patient Organisation for Primary Immunodeficiencies
NHS Greater Glasgow & Clyde
North of Scotland Cancer Network
Pediatric Blood & Cancer
Paediatric European Network for Treatment of AIDS
Public Health Agency of Canada
Royal College of Paediatrics and Child Health
Scottish Haematology Society (SHS)

Key	
ACIP	Advisory Committee for Immunization Practices
CCLG	Children’s Cancer and Leukaemia Group
SHS	Scottish Haematology Society
BCSH	British Committee for Standards in Haematology
BGS	British Geriatrics Society
BHIVA	British HIV Association
BSR	British Society for Rheumatology
BTS	British Transplantation Society
CDC	Centers for Disease Control
CHIVA	Children’s HIV Association
DH	Department of Health – The Green Book
EBMT	European Bone Marrow Transplant
HIS	Healthcare Improvement Scotland
HPS	Health Protection Scotland – TRAVAX
HSE	Health Service Executive (Ireland)
IDSA	Infectious Diseases Society of America
IM	Immunisation Scotland
IPOPI	International Patient Organisation for Primary Immunodeficiencies
LA	Lymphoma Association
NES	NHS Education Scotland
NOSCAN	North of Scotland Cancer Network
PBC	Pediatric Blood & Cancer
PENTA	Paediatric European Network for Treatment of AIDS
PHE	Public Health England
PHAC	Public Health Agency of Canada
RCPCH	Royal College of Paediatrics and Child Health

Guidance

Year	Document Title	Author	Key message(s)
2016	Vaccination Policy (Post HSC Transplantation) http://scothaem.org/vaccination-policy-post-hsc-transplantation.asp .	SHS	The guidance recommendations of immunisation following Bone Marrow Transplant (BMT), also includes advice on vaccination of household contacts which may also be appropriate against certain infections to reduce the chance of cross infection.
2016	Addiction of New Immunocompromised Section on TRAVAX. Guidance and additional resources on Vaccination in the Immunocompromised (including HIV) traveller and Vaccination of Asplenic travellers is available on the TRAVAX website. TRAVAX can be access at the following address www.travax.nhs.uk .	HPS - TRAVAX	TRAVAX aims to give evidence-based, but also practical, information and is well-suited to the clinical setting. HPS undertakes continual monitoring of travel related health risks and available preventive measures and the travel health team is actively involved in research, education and delivery of travel health services.
2016	Immunoglobulin Handbook https://www.gov.uk/government/publications/immunoglobulin-when-to-use .	PHE	PHE's immunoglobulin handbook, providing guidance on administering immunoglobulin to prevent serious disease
2015	Geretti AM, Brook G, Cameron C, Chadwick D, French N, Heyderman R, et al. British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015. HIV Med 2016;17 Suppl 3:s2-s81 PMID: 27568789. (http://onlinelibrary.wiley.com/doi/10.1111/hiv.12424/abstract).	BHIVA	The revised guidance provide updated, GRADE-based recommendations on the use of vaccines in HIV-positive adults. The update contains important new guidance regarding the use of new vaccines against human papillomavirus (HPV), shingles (herpes zoster) and pneumococcus.
2015	Children's HIV Association. Vaccination of HIV infected children (UK schedule, 2015) http://www.chiva.org.uk/guidelines/immunisation/ .	CHIVA	These CHIVA immunisation guidelines are updated on an annual basis.
2015	North of Scotland Cancer Network – Guidelines and Protocol http://www.noscan.scot.nhs.uk/guidelinesandprotocols/Pages/default.aspx .	NOSCAN	Contains information about cancer-related protocols and Clinical Management guidelines for health professionals in the North of Scotland.

Year	Document Title	Author	Key message(s)
2015	UK Guidelines for Kidney and Pancreas Transplantation in patients with HIV http://www.bts.org.uk/Documents/Guidelines/Active/Kidney%20Txp%20in%20HIV%20Guidelines%20-%20Mar%202015%20FINAL.pdf .	BTS	The aim is to provide a comprehensive summary of all aspects of assessment, selection and management of the HIV-positive transplant candidate. This document should be read in conjunction with existing guidelines regarding the management of non-HIV-infected kidney transplant recipients , but will focus on areas of special relevance to HIV-infected kidney and pancreas transplant recipients.
2014	Vaccinations for Paediatric Patients Treated With Standard-Dose Chemotherapy and Haematopoietic Stem Cell Transplantation (HSCT) Recipients. (<i>Vax paediatric</i>)	CCLG	Provides guidance on Vaccinations for Paediatric Patients Treated With Standard-Dose Chemotherapy and Haematopoietic Stem Cell Transplantation (HSCT) Recipients
2014	Immunisation of individuals with underlying medical conditions: the green book, chapter 7 https://www.gov.uk/government/publications/immunisation-of-individuals-with-underlying-medical-conditions-the-green-book-chapter-7 .	DH	Some medical conditions increase the risk of complications from infectious diseases, and children and adults with such conditions should be immunised as a matter of priority. These groups may also require additional vaccinations or additional doses of vaccines to provide adequate protection.
	Foreign travel and lymphoma: infections and vaccinations http://www.lymphomas.org.uk/about-lymphoma/living-with-lymphoma/foreign-travel-and-lymphoma-infections-and-vaccinations#vaccinations .	LA	Provides information on vaccinations which are safer for people with lymphoma.
2013	Primary immunodeficiencies – Vaccines and primary immunodeficiencies http://www.piduk.org/static/media/up/vaccines.pdf .	IPOPI	

Year	Document Title	Author	Key message(s)
2012	<p>Guidance on the vaccination of HIV infected children in Europe http://www.ingentaconnect.com/content/bsc/hiv/2012/00000013/00000006/art00002.</p> <p>Menson EN, Mellado MJ, Bamford A, Castelli G, Duiculescu D, Marczyńska M, Navarro M, Scherpbier HJ, Heath PT; Paediatric European Network for Treatment of AIDS (PENTA) Vaccines Group; PENTA Steering Committee; Children's HIV Association (CHIVA) (2012) Guidance on vaccination of HIV infected children in Europe. HIV Med 13(6):333-6.</p>	PENTA	Provides guidance on vaccinating HIV-infected children.
2011	<p>Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Br J Haematol 155(3):308-17. http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2011.08843.x/epdf.</p>	BCSH	Review prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force.
2011	<p>Vaccination Programmes in Older People – BGS Best Practice Guide http://www.bgs.org.uk/index.php/topresources/publicationfind/goodpractice/1158-vaccinationbpg.</p>	BGS	Infectious diseases account for a significant proportion of hospital admissions and deaths in the elderly. Influenza and pneumonia are of particular importance, and effective vaccines exist which are recommended for people aged over 65 years.
2002	<p>Vaccination in the Immunocompromised Person Guidelines for the patient taking immunosuppressants, steroids and the new biological therapies http://www.rheumatology.org.uk/includes/documents/cm_docs/2009/v/vaccinations_in_the_immunocompromised_person.pdf.</p>	BSR	Provides advice on vaccination of Immunocompromised person taking immunosuppressants, steroids and the new biological therapies
2002	<p>Immunisation of the Immunocompromised Child. Best Practice Statement http://www.rcpch.ac.uk/sites/default/files/asset_library/Publications//Immunocomp.pdf.</p>	RCPCH	Best practice statement on immunisation of Immunocompromised child.

Surveillance

Year	Document Title	Author	Key message(s)
2013	Surveillance and monitoring for vaccine safety: the green book, chapter 9 https://www.gov.uk/government/publications/surveillance-and-monitoring-for-vaccine-safety-the-green-book-chapter-9 .	DH	This chapter describes the process of vaccine safety monitoring in the UK and the reporting of adverse events following immunisation (AEFIs). It also describes the mechanism for the reporting of suspected defects in vaccines or in the devices used for the administration of vaccines.

Tools / Implementation

Year	Document Title	Author	Key message(s)
2015	Screening Tool for Contraindications for Shingles Vaccine http://www.hps.scot.nhs.uk/immvax/shinglesvaccine.aspx .	HPS	This tool can be used to aid identification of patients who are contra-indicated for shingles vaccine, which is a live vaccine

Education Resources

Year	Document Title	Author	Key message(s)
2016	Immunisation Scotland – Vaccines and diseases http://www.immunisationscotland.org.uk/ .	IM	Educational resources for Scotland contains immunisation schedules.
2016	NHS Education Scotland http://www.nes.scot.nhs.uk/education-and-training/by-theme-initiative/public-health/health-protection/immunisation.aspx .	NES	
2010	Skincare of Patients Receiving Radiotherapy Best Practice Statement Mar 2010 http://www.healthcareimprovementscotland.org/previous_resources/best_practice_statement/radiotherapy_skincare.aspx . Skincare of Patients Receiving Radiotherapy Quick Reference Guide Mar 2010 http://www.healthcareimprovementscotland.org/previous_resources/best_practice_statement/radiotherapy_skincare.aspx .	HIS	Contains best practice statements in relation to skincare of patients receiving radiotherapy and promote a consistent and cohesive approach of care.

Literature Reviews

Year	Document Title	Author	Key message(s)
2011	Influenza Vaccination for Immunocompromised Patients: Systematic Review and Meta-Analysis from a Public Health Policy Perspective. http://eprints.lancs.ac.uk/56710/1/journal.pone.0029249.pdf .	Beck et al	This systematic review and meta-analysis assesses influenza vaccination for immunocompromised patients in terms of preventing influenza-like illness and laboratory confirmed influenza, serological response and adverse events.

Research

Year	Document Title	Author	Key message(s)
2016	Protection against vaccine preventable diseases in children treated for acute lymphoblastic leukemia. https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.26187	de la Fuente Garcia et al Pediatric Blood & Cancer	This study supports the need for a systematic booster vaccination program after treatment and reinforces the need for household members' immunization.
2015	Re-vaccination follow – up study (Follow up project)	GGC	Patients who have had a haemopoietic stem cell transplant, whether autologous or allogeneic, should undergo a programme of re-vaccination following the procedure.

International Guidance

Year	Document Title	Author	Key message(s)
2016	Chemotherapy and Post Hematopoietic Stem Cell Transplant Immunisation guideline http://www.mvec.vic.edu.au/immunisation-references/cancer-immunisation-guideline-chemotherapy-and-post-hematopoietic-stem-cell-transplant/ .	MVEC	Contains information from Melbourne Vaccine education Centre on Cancer Immunisation Guideline: Chemotherapy and Post Hematopoietic Stem Cell Transplant.
2015	Vaccination of Persons with Primary and Secondary Immune Deficiencies https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/a/immuno-table.pdf .	CDC	

Year	Document Title	Author	Key message(s)
2015	Immunisation of immunocompromised persons http://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter3.pdf .	HSE	This chapter has guidance on <ul style="list-style-type: none"> • General Principles of Immunisation of Immunocompromised Persons • Cancer patients • Transplantation <ul style="list-style-type: none"> - Haematopoietic Stem Cell Transplant - Solid organ transplant candidates and recipients • Corticosteroid therapy • Immunomodulatory treatment • Functional or anatomic asplenia, hyposplenism • HIV • Primary Immunodeficiency • Immunocompetent household contacts of immunocompromised persons
2014	Immunisation of Immunocompromised Persons http://www.phac-aspc.gc.ca/publicat/cig-gci/p03-07-eng.php .	PHAC	
2013	IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host http://www.idsociety.org/Templates/Content.aspx?id=32212256011 . Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I, Infectious Diseases Society of America (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58(3):309-18.	IDSA	

Year	Document Title	Author	Key message(s)
2013	Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6225a3.htm .	CDC	Recommends routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) for children aged 6–18 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants who have not previously received PCV13. PCV13 should be administered to these children regardless of whether they received the 7-valent pneumococcal conjugate vaccine (PCV7) or the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Recommendations for PPSV23 use for children in this age group remain unchanged.
2012	Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm .	CDC	Recommends routine use of 13-valent pneumococcal conjugate vaccine for adults aged ≥19 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants.